understanding cholesterol effects of adalimumab by new techniques was another goal of gelfand and mehta's study.
.
.
.
.
. taking ustekinumab�a biologic that targets a different aspect of the immune system," gelfand said.
.
.
over the years, i�ve talked to reporters who are solidly addicted to obfuscations. like any addict, they have an army of excuses to rationalize their behavior.
.
.
.